TRIPLE THERAPY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE: FROM ANALYSIS TO PRACTICE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chronic obstructive pulmonary disease (COPD) has become one of the leading non-infectious problems of medicine over the last three decades. The presence of three groups of inhaled drugs, each of which is well studied in COPD, has empirically led to the use of triple combinations in the treatment of COPD. Data on the effectiveness and prevalence of triple therapy (TT) are still fewand sometimes contradictory, which made this literature review as relevant. The results of randomized clinical trials of combinations of fluticasone furoate/ vilanterol/umeclidinium, budesonide/formoterol fumorate/glycopyrronium bromide and beclomethasone dipropionate/formoterol fumorate/glycopyrronium bromide, as well as combinations of tiotropium bromide with budesonide/formoterol fumorate and a combination of tiotropium bromide with a fluticasone propionate/salmeterol are presented. TT, which includes two long-acting bronchodilators and an inhaled glucocorticosteroid, is widely used in actual clinical practice in different countries, despite the fact that indications for its use are limited to severe COPD with severe symptoms and frequent exacerbations. Conducted clinical studies have proved the safety of TT, but the evidence base for the effectiveness of TT remains insufficient. Obviously, this variant of therapy should be studied not only in COPD with different severity, but also among patients with different phenotypes. On the one hand, this will allow to optimize treatment, on the other hand, to save the resources of the healthcare system and patients.

Full Text

Restricted Access

About the authors

A. A Vizel

FSBEI HE "Kazan State Medical University" of RMH

Email: lordara@mail.ru
MD, Professor, Head of Department of Phthisiopulmonology

I. Yu Vizel

FSBEI HE "Kazan State Medical University" of RMH

Department of Phthisiopulmonology

I. N Salakhova

FSBEI HE "Kazan State Medical University" of RMH

Department of Phthisiopulmonology

A. R Vafina

FSBEI HE "Kazan State Medical University" of RMH

Department of Phthisiopulmonology

References

  1. Sestini P., Ram F.S. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2000;(2):CD001495.
  2. Tennant R.C., Erin E.M., Barnes P.J., Hansel T.T. Long-acting beta2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified? Curr. Opin. Pharmacol. 2003;3(3):270-76.
  3. Hall T.G., Kasik J.E., Bedell G.N., Schaiff R.A. The efficacy of inhaled beclomethasone in chronic obstructive airway disease. Pharmacotherapy. 1989;9(4):232-39.
  4. Авдеев C.H. Небулайзерная терапия обструктивных заболеваний легких. Consilium Medicum. 2011;13(3):36-42.
  5. Cazzola M., Dahl R. Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD. Chest. 2004;126(1):220-37.
  6. Briggs A.H., Glick H.A., Lozano-Ortega G., Spencer M., Calverley P.M., Jones P.W., Vestbo J. TOwards a Revolution in COPD Health (TORCH) investigators. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur. Respir. J. 2010;35(3):532-39.
  7. Rodrigo G.J., Price D., Anzueto A., Singh D., Altman P., Bader G., Patalano F., Fogel R., Kostikas K. LABA/LAMA combinatbns vers us LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon Dis. 2017;12:907-22.
  8. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). Updated 2017. http://www.ginasthma.org
  9. Brusselle G., Price D., Gruffydd-Jones K, Miravitlles M., Keininger D.L., Stewart R., Baldwin M., Jones R.C. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:2207-17.
  10. Ferroni E., Belleudi V., Cascini S., Di Martino M., Kirchmayer U., Pistelli R., Patorno E., Formoso G., Fusco D., Региссі C.A., Davoli M., Agabiti N.; OUTPUL Study Group. Role of tiotropium in reducing exacerbations of chronic obstructive pulmonary disease when combined with long-acting ß2-agonists and inhaled corticosteroids: The OUTPUL Study. J. Clin. Pharmacol. 2016;56(11 ):1423-32.
  11. Kim S.A., Lee J.H., Kim E.X., Kim Т.Н., Kim W.J., Lee J.H., Yoon H.I., Baek S., lee J.S., Oh Y.M., Lee S.D. Outcome of inhaler withdrawal in patients receiving triple therapy for COPD. Tuberc. Respir. Dis. (Seoul). 2016;79(1 ):22-30.
  12. Simeone J.C., Luthra R., Kaila S., Pan X., Bhagnani T.D., Liu J., Wilcox Т.К. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int. J. Chron. Obstruct. Pulmon. Dis. 2016;12:73-83.
  13. Rojas-Reyes M.X., GarcíaMorales O.M., Dennis R.J., Karner С. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;(6):CD008532.
  14. Лещенко И. В. Новые горизонты в профилактике обострений хронической обструктивной болезни легких. Практич. пульмонология. 2016;3:26-36.
  15. O'Donnell D.E., Aaron S., Bourbeau J., Hernandez P., Marciniuk D.D., Balter M., et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can. Resp. J. 2007;14(Suppl. B):5-32.
  16. Gaebel K., Mclvor R.A., Xie F., Blackhouse G., Robertson D., Assasi N., Hernandez P., Goeree R. Triple therapy for the management of COPD: a review. COPD. 2011 ;8(3):206-43.
  17. Salama R.O., Young P.M., Rogueda P., Lallement A., Hiev I., Traini D. Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease? Expert. Opin. Pharmacother. 2011;12(12):1913-32.
  18. Adi H., Young P.M., Traini D. Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers. J. Pharm. Pharmacol. 2012;64(9):1245-53.
  19. Cazzola M., Matera M.G. Triple combinations in chronic obstructive pulmonary disease - is three better than two? Expert. Opin. Pharmacother. 2014;15( 17):2475-78.
  20. Montuschi P., Malerba M., Macis G., Mores N., Santini G. Triple inhaled therapy for chronic obstructive pulmonary disease. Drug. Discov. Today. 2016;21(1 J): 1820-27.
  21. Емельянов A.B. Ингаляционные глюкокортикоиды при хронической обструктивной болезни легких: каково их место в лечении этого заболевания? РМЖ. 2017;3:22 7-31.
  22. Авдеев С.Н., Айсанов З.Р., Белевский A.C., Визель A.A., Зырянов С.К., Игнатова Г.Л., Княжеская Н.П., Лещенко И.В., Овчаренко С.И., Синопальников А.И., Степанян И.Э., Трофимов В.И. Новые возможности в профилактике обострений хронической обструктивной болезни легких. Заключение группы специалистов Российского респираторного общества. Пульмонология. 2017;27( 1 ): 108-13.
  23. Welte T., Miravitlles М., Hernandez P., Eriksson G., Peterson S., Polanowski T., Kessler R. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit Care Med. 2009; 180(8):741 -50.
  24. Lee S.D., Xie C.M., Yunus F., Itoh Y., Ling X., Yu W.C., Kiatboonsri S. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: A randomized, multicentre study in East Asia. Respirology. 2016;21(1):119-27.
  25. Jung K.S. Park H.Y., Park S.Y., Kim S.K., Kim Y.K., Shim J.J., Moon H.S., Lee K.H., Yoo J.H., lee S.D.; Korean Academy of Tuberculosis and Respiratory Diseases study group; Korea Chronic Obstructive Pulmonary Disease study group. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study Respir. Med. 2012;106(3):382-89.
  26. Saito T., Takeda A., Hashimoto K., Kobayashi A., Hayamizu T., Hagan G.W. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with triple, int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:2393-404.
  27. Баранова И.И., Лещенко И.В. Влияние базисной терапии на клинические симптомы, качество жизни и системное воспаление у больных хронической обструктивной болезнью легких. Клин. мед. 2013;12:21-5.
  28. Singh D., Schröder-Babo W., Cohuet G., Muraro A., Bonnet-Gonod F., Petruzzelli S., Hoffmann M., Siergiejko Z.; TRIDENT study investigators. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study). Respir. Med, 2016; 114:84-90.
  29. Singh D., Papi A., Corradi M., Pavlišová I., Montagna I., Francisco C., Cohuet G., Vezzoli S., Scuri M., Vestbo J. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048/963-73.
  30. Vestbo J., Papi A., Corradi M., Blazhko V., Montagna I., Francisco C., Cohuet G., Vezzoli S., Scuri M., Singh D. Single inhaler extra fine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919-29.
  31. Lal C., Strange C. Spotlight on fluticasone furoate/umedidinium/vilanterol in COPD: design. development, and potential place in therapy. Int. J. Chron. Obstruct. Pulmon. Dis. 2016;12:135-40.
  32. Lipson D.A., Barnacle H., Birk R., Brealey N., locantore N., Lomas D.A., Ludwig-Sengpiel A., Mohindra R., Tabberer M., Zhu C.Q., Pascoe S.J. FULFIL trial: once-daily triple therapy in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2017 Apr 4.
  33. Pascoe S.J., Lipson D.A., bocantore N., Barnacle H., Brealey N., Mohindra R., Dransfield M.T., Pavord I., Barnes N. A phase Hi randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur. Respir. J. 2016;48(2):320-30.
  34. Manderville J.R. Appropriateness of triple therapy after COPD exacerbation. О HP. 2 013;66( 1 ):41 -2.
  35. Kwak M.S., Kim E., Jang E.J., Kim H.J., Lee C.H. The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods, int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:2365-76.
  36. Aaron S.D., Vandemheen K.L., Fergusson D., Maltais F., Bourbeau J., Goldstein R., Balter M., O'Donnell D., Mclvor A., Sharma S., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann, Intern, Med. 2007;146:545-55.
  37. Tashkin D.P., Celli В., Senn S., Burkhart D., Kesten S., Menjoge S., Decramer M., Investigators US. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008;359:1543-54.
  38. Martinez F.J., Calverley P.M., Goehring U.M., Brose M., Fabbri L.M., Rabe K.F. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385: 857-66.
  39. Calverley P., Vlies В. A rational approach to single, dual and triple therapy in COPD. Respirology. 2016;21 (4):581 -89.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies